Igor T. Gavrilovic

4.0k total citations · 1 hit paper
42 papers, 2.0k citations indexed

About

Igor T. Gavrilovic is a scholar working on Genetics, Neurology and Pathology and Forensic Medicine. According to data from OpenAlex, Igor T. Gavrilovic has authored 42 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Genetics, 22 papers in Neurology and 12 papers in Pathology and Forensic Medicine. Recurrent topics in Igor T. Gavrilovic's work include Glioma Diagnosis and Treatment (24 papers), CNS Lymphoma Diagnosis and Treatment (14 papers) and Brain Metastases and Treatment (12 papers). Igor T. Gavrilovic is often cited by papers focused on Glioma Diagnosis and Treatment (24 papers), CNS Lymphoma Diagnosis and Treatment (14 papers) and Brain Metastases and Treatment (12 papers). Igor T. Gavrilovic collaborates with scholars based in United States, Switzerland and France. Igor T. Gavrilovic's co-authors include Jerome B. Posner, Lauren E. Abrey, Lisa M. DeAngelis, Thomas Kaley, Craig Nolan, Adı́lia Hormigo, Antonio Omuro, Joachim Yahalom, Andrew B. Lassman and Katherine S. Panageas and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Igor T. Gavrilovic

40 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Brain metastases: epidemiology and pathophysiology

2005 689 citations Igor T. Gavrilovic, Jerome B. Posner Journal of Neuro-Oncology profile →

Peers

Countries citing papers authored by Igor T. Gavrilovic

Since Specialization

Citations

This map shows the geographic impact of Igor T. Gavrilovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Igor T. Gavrilovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Igor T. Gavrilovic more than expected).

Fields of papers citing papers by Igor T. Gavrilovic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Igor T. Gavrilovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Igor T. Gavrilovic. The network helps show where Igor T. Gavrilovic may publish in the future.

Co-authorship network of co-authors of Igor T. Gavrilovic

This figure shows the co-authorship network connecting the top 25 collaborators of Igor T. Gavrilovic. A scholar is included among the top collaborators of Igor T. Gavrilovic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Igor T. Gavrilovic. Igor T. Gavrilovic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immune Checkpoint Inhibitor Therapy for Aggressive Pituitary Neuroendocrine Tumors 2025 ·The Journal of Clinical Endocrinology & Metabolism ·Andrew Lin, Vasilisa A. Rudneva, (unknown), Nazanin Majd, Rajiv Magge, Soma Sengupta, Bernard Goichot, Anna F. Piotrowski, Igor T. Gavrilovic, Odelia Cooper, Marc K. Rosenblum, Thomas Kaley, Ingo K. Mellinghoff, Robert J. Young, Mark T.A. Donoghue, Viviane Tabar, Eliza B. Geer	5
2	Combination Olaparib and Temozolomide for the Treatment of Glioma 2022 ·Neurology ·Lauren Schaff, (unknown), Andrew Lin, Subhiksha Nandakumar, Christian Grommes, Alexandra Miller, Igor T. Gavrilovic, Craig Nolan, Elena Pentsova, Ingo K. Mellinghoff, Thomas Kaley	7
3	Concurrent Olaparib and Temozolomide for Recurrent Glioma (P5-9.005) 2022 ·Neurology ·(unknown), Andrew Lin, Alexandra Miller, Igor T. Gavrilovic, Craig Nolan, Elena Pentsova, Ingo K. Mellinghoff, Thomas Kaley, Lauren Schaff	0
4	Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study 2022 ·BMC Cancer ·Lauren Schaff, (unknown), Dean Carlow, Ryan Schofield, Igor T. Gavrilovic, Alexandra Miller, Jacqueline Stone, Anna F. Piotrowski, Uğur Sener, Anna Skakodub, Edward P. Acosta, Kevin J. Ryan, Ingo K. Mellinghoff, Lisa M. DeAngelis, Burt Nabors, Christian Grommes	8
5	Pilot Study of Glucarpidase in Combination with Rituximab and Methotrexate (MTX) in CNS Lymphoma (CNSL) (1409) 2020 ·Neurology ·Lauren Schaff, Uğur Sener, Igor T. Gavrilovic, Alexandra Miller, Jacqueline Stone, Anna Skakodub, (unknown), (unknown), Edward P. Acosta, (unknown), Kevin J. Ryan, Dean Carlow, Burt Nabors, Christian Grommes	1
6	Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas 2019 ·Journal of Neuro-Oncology ·(unknown), (unknown), (unknown), Igor T. Gavrilovic, Thomas Kaley	12
7	Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma 2019 ·Journal of Neuro-Oncology ·Thomas Kaley, Katherine S. Panageas, Ingo K. Mellinghoff, Craig Nolan, Igor T. Gavrilovic, Lisa M. DeAngelis, Lauren E. Abrey, Eric C. Holland, Andrew B. Lassman	43
8	Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL) 2016 ·Annals of Oncology ·Christian Grommes, Igor T. Gavrilovic, Thomas Kaley, Craig Nolan, Antonio Omuro, J. M. Wolfe, Elena Pentsova, (unknown), Ingo K. Mellinghoff, Lisa M. DeAngelis	13
9	A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation 2015 ·Neuro-Oncology ·Vaios Hatzoglou, Jonathan T. Yang, Antonio Omuro, Igor T. Gavrilovic, Gary A. Ulaner, (unknown), (unknown), Kaitlin M. Woo, Zhigang Zhang, Kyung K. Peck, Kathryn Beal, Robert J. Young	60
10	Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients 2015 ·Neuro-Oncology ·(unknown), (unknown), Alissa A. Thomas, Thomas Kaley, Sasan Karimi, Igor T. Gavrilovic, Kaitlin M. Woo, Zhigang Zhang, Julio Arévalo‐Pérez, Andrei I. Holodny, Marc K. Rosenblum, Robert J. Young	28
11	Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma 2014 ·Neuro-Oncology ·Thomas Kaley, Patrick Y. Wen, David Schiff, Keith L. Ligon, Sam Haidar, Sasan Karimi, Andrew B. Lassman, Craig Nolan, Lisa M. DeAngelis, Igor T. Gavrilovic, Andrew D. Norden, Jan Drappatz, Eudocia Q. Lee, Benjamin Purow, Scott R. Plotkin, Tracy T. Batchelor, Lauren E. Abrey, Antonio Omuro	194
12	Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma 2012 ·Neuro-Oncology ·Antonio Omuro, Timothy A. Chan, Lauren E. Abrey, Mustafa Khasraw, Anne S. Reiner, Thomas Kaley, Lisa M. DeAngelis, Andrew B. Lassman, Craig Nolan, Igor T. Gavrilovic, Adı́lia Hormigo, (unknown), Adriana Heguy, Andrew Kaufman, Jason T. Huse, Katherine S. Panageas, Andreas F. Hottinger, Ingo K. Mellinghoff	74
13	Temozolomide or bevacizumab for spinal cord high-grade gliomas 2012 ·Journal of Neuro-Oncology ·Thomas Kaley, (unknown), Igor T. Gavrilovic	39
14	Pearls: Primary Brain Tumors 2010 ·Seminars in Neurology ·Craig Nolan, Igor T. Gavrilovic	1
15	Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma 2009 ·Journal of Clinical Oncology ·Jennifer Clarke, Fábio M. Iwamoto, Joohee Sul, Katherine S. Panageas, Andrew B. Lassman, Lisa M. DeAngelis, Adı́lia Hormigo, Craig Nolan, Igor T. Gavrilovic, Sasan Karimi, Lauren E. Abrey	128
16	Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas 2007 ·Journal of Neuro-Oncology ·Gaurav Shah, (unknown), Steven S. Rosenfeld, Igor T. Gavrilovic, Lauren E. Abrey, Andrew B. Lassman	11
17	A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases 2007 ·Journal of Neuro-Oncology ·Fábio M. Iwamoto, Antonio Omuro, Jeffrey J. Raizer, Craig Nolan, (unknown), Andrew B. Lassman, Igor T. Gavrilovic, Lauren E. Abrey	36
18	Diagnosis and treatment of primary central nervous system lymphoma 2005 ·Current Oncology Reports ·Igor T. Gavrilovic, Lauren E. Abrey	9
19	Brain metastases: epidemiology and pathophysiology breakdown → 2005 ·Journal of Neuro-Oncology ·Igor T. Gavrilovic, Jerome B. Posner	689
20	Primary central nervous system lymphoma 2004 ·Current Oncology Reports ·Igor T. Gavrilovic, Lauren E. Abrey	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact